MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms MABTENANCE
- 07 Jun 2017 Biomarkers information updated
- 23 Dec 2013 Planned end date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 23 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.